Login / Signup

Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.

Jennifer ZhouDanny LiewDavid M KayeSophia ZoungasDion Stub
Published in: Circulation. Cardiovascular quality and outcomes (2022)
In patients with heart failure with preserved ejection fraction, adding empagliflozin to standard care is likely to be cost-effective when compared with standard care alone in the Australian health care setting.
Keyphrases
  • healthcare
  • ejection fraction
  • palliative care
  • aortic stenosis
  • quality improvement
  • affordable care act
  • pain management
  • heart failure
  • chronic pain
  • aortic valve
  • health insurance
  • health information